Defense Bar Commentary Highlights Practice Points for Biotech Securities Litigation

A panel of corporate advisors updated their 2017 survey of securities litigation involving development-stage biotech companies, providing important practice points for the institutional investor and concluding that biotech start-ups do not pose a greater securities class action risk compared to other companies. Stronger cases involved plaintiffs making credible allegations that defendants intentionally misrepresented data or facts about their interactions with the FDA, omitted adverse regulator feedback, or presented misleading information about regulatory milestones or assessments.

10-Q&A Episode 9: Conversation with Futurist and Innovator Ajay Raju (LAW ’96)

In Jon Shahar’s final episode, he sits down with Ajay Raju (LAW ’96) to discuss disruption and innovation in the legal practice, the role of “counsel”, and Philadelphia’s future as a hub for innovation. Interviewer:Jon Shahar  Guests:  Ajay Raju (LAW ’96), Managing Partner & Founder of Raju LLP & IO Law Firm